26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 28 / Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000015587 | 2014/11/04 | 03/11/2014 | Clinical trial with NaPPS for HTLV-1-associated myelopathy (HAM) patients | HTLV-1-associated myelopathy (HAM) | period of intervention: 12 weeks 0-4 weeks: Normal saline solution by subcutaneous injection 4-12 weeks: NaPPS(Pentosan Polysulfate sodium) 50 mg by subcutaneous injection period of intervention: 12 weeks 0-4 weeks: Normal saline solution by subcutaneous injection 4-12 weeks: NaPPS(Pentosan Polysulfate sodium) 100 mg by subcutaneous injection period of intervention: 12 weeks 0-4 weeks: NaPPS 100mg/week by subcutaneous injection 4-12 weeks: NaPPS(Pentosan Polysulfate sodium) 50 mg by subcutaneous injection period of intervention: 12 weeks 0-4 weeks: NaPPS 100mg/week by subcutaneous injection 4-12 weeks: NaPPS(Pentosan Polysulfate sodium) 100 100 mg by subcutaneous injection | ReqMed Company, Ltd | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 12 | Phase 2 | Japan |